Clinical Study on Dilong Jiangya Capsule in Treatment of Essential Hypertension with Subclinical Atherosclerosis of Hyperactivity of Liver Yang Type / 中国中医药信息杂志

ABSTRACT

Objective To investigate the synergistic antihypertensive effect of Dilong Jiangya Capsules on patients with essential hypertension with subclinical atherosclerosis of liver yang hyperactivity type and its effect on arteriosclerosis. Methods Totally 120 patients with essential hypertension with subclinical atherosclerosis were randomly divided into treatment group (60 cases) and control group (60 cases). Control group received antihypertensive treatment by following the individual, low-dose, long-term, combined principle, while treatment group was given Dilong Jiangya Capsules on the basis of control group, one capsule per time, twice a day, orally taken during early morning and bedtime. The treatment for both groups lasted for six weeks. Blood pressure, carotid artery intima-media thickness (IMT), pulse wave velocity (PWV) and ankle-brachial index (ABI) were observed before and 2, 4 and 6 weeks after treatment. Blood pressure clinical efficacy was evaluated. Results Two and three cases were lost in the treatment group and control group, respectively. The total effective rate was 91.38% (53/58) in the treatment group and 82.46% (47/57) in the control group, and the treatment group was significantly better than the control group (P<0.05). Compared with before treatment, the blood pressure of the two groups was significantly lower (P<0.05), and the treatment group was significantly lower than the control group (P<0.05). Compared with before treatment, the levels of IMT and PWV in both groups significantly decreased at 2 and 4 weeks of treatment, and ABI at 2, 4 and 6 weeks of treatment decreased significantly (P<0.05). There was statistical difference in IMT and PWV between the two groups at 4 weeks of treatment (P<0.05). There was statistical difference in ABI between the two groups at 2 and 4 weeks of treatment (P<0.05). There was statistical difference in IMT, PWV and ABI between the two groups at 6 weeks of treatment (P<0.05). Conclusion Dilong Jiangya Capsules combined with conventional antihypertensive treatment of essential hypertension with subclinical atherosclerosis can enhance the antihypertensive effect, and improve IMT, PWV and ABI to some extent.